Comparative Pharmacology
Head-to-head clinical analysis: KAPVAY versus LOFEXIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAPVAY versus LOFEXIDINE HYDROCHLORIDE.
KAPVAY vs LOFEXIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
Alpha-2 adrenergic receptor agonist; reduces central sympathetic outflow by binding to presynaptic alpha-2 receptors in the brainstem, decreasing norepinephrine release.
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
0.2 mg orally twice daily, titrate by 0.2-0.4 mg/day every 1-2 days to maximum 2.4 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates.
Terminal elimination half-life is 11-13 hours in patients with normal renal function; prolonged to up to 40 hours in renal impairment.
Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible.
Primarily renal (approximately 80-90% as unchanged drug and metabolites, with 20-30% unchanged); minor fecal excretion (<5%).
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist